MEK Inhibitor-Associated Retinopathy (MEKAR)





History of Present Illness (HPI)


A 69-year-old woman with a history of cutaneous melanoma complains of a change in her vision for the last month or so. She has difficulty describing her symptoms, but she reports that things are just a bit out of focus in both eyes (OU). She denies any other eye symptoms and has not had any recent changes to her health or recent hospitalizations.


Questions to Ask





  • Have you started any new medications, either for your melanoma or anything else?



  • Are you taking any steroids?



She responds that she recently started a new drug to treat melanoma based on “the DNA in the melanoma,” but is unsure of its name. A review of her oncology outpatient notes shows that she is on trametinib, an inhibitor of mitogen-activated protein kinases (MEK). She denies corticosteroid use.



Exam












































OD OS
Vision 20/25 20/20
Intraocular pressure (IOP) 14 15
Lids and lashes: Normal Normal
Sclera/conjunctiva: White and quiet White and quiet
Cornea: Clear Clear
Anterior chamber (AC): Deep and quiet Deep and quiet
Iris: Flat Flat
Lens: 1+ nuclear sclerosis (NS) 1+ NS
Dilated fundus examination (DFE): See Fig. 57.1A See Fig. 57.1B


Assessment


Serous retinal detachments, left eye greater than right eye (OS > OD)




Fig. 57.1


(A) Color fundus photograph of the right eye shows clear media and a subtle, subretinal, yellow-colored lesion inferior to the fovea. (B) Color fundus photograph of the left eye shows clear media and multiple blebs of subretinal fluid in the posterior pole, including a broad foveal detachment.

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Apr 3, 2021 | Posted by in OPHTHALMOLOGY | Comments Off on MEK Inhibitor-Associated Retinopathy (MEKAR)

Full access? Get Clinical Tree

Get Clinical Tree app for offline access